MENU
+Compare
HLUBF
Stock ticker: OTC
AS OF
Aug 11 closing price
Price
$4.59
Change
-$0.15 (-3.16%)
Capitalization
5.86B

HLUBF H. Lundbeck A/S Forecast, Technical & Fundamental Analysis

Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products... Show more

HLUBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for HLUBF with price predictions
Aug 15, 2025

HLUBF sees MACD Histogram crosses below signal line

HLUBF saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 13, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 20 instances where the indicator turned negative. In of the 20 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Momentum Indicator moved below the 0 level on August 11, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HLUBF as a result. In of 22 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.199) is normal, around the industry mean (16.657). P/E Ratio (8.309) is within average values for comparable stocks, (72.172). Projected Growth (PEG Ratio) (5.973) is also within normal values, averaging (4.696). Dividend Yield (0.030) settles around the average of (0.031) among similar stocks. P/S Ratio (1.233) is also within normal values, averaging (40.190).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HLUBF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HLUBF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

View a ticker or compare two or three
HLUBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
N/A
Address
Ottiliavej 9
Phone
+45 36301311
Employees
5681
Web
https://www.lundbeck.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYPMX188.31N/A
N/A
Rydex Precious Metals Inv
IVIPX30.61N/A
N/A
VY® Invesco Equity and Income S2
KLCSX20.96N/A
N/A
Federated Hermes Kaufmann Large Cap R6
TRWIX24.93N/A
N/A
Transamerica International Equity I2
CGFCX72.63-0.05
-0.07%
American Funds Growth Fund of Amer 529C

HLUBF and Stocks

Correlation & Price change

A.I.dvisor tells us that HLUBF and HLBBF have been poorly correlated (+18% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HLUBF and HLBBF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HLUBF
1D Price
Change %
HLUBF100%
N/A
HLBBF - HLUBF
18%
Poorly correlated
N/A
HLNCF - HLUBF
7%
Poorly correlated
+2.77%
ESAIY - HLUBF
5%
Poorly correlated
+2.73%
AKAN - HLUBF
2%
Poorly correlated
-0.73%
HLN - HLUBF
1%
Poorly correlated
+0.10%
More

Groups containing HLUBF

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HLUBF
1D Price
Change %
HLUBF100%
N/A
Pharmaceuticals
category (393 stocks)
-0%
Poorly correlated
-0.36%
Pharmaceuticals: Generic
category (227 stocks)
-0%
Poorly correlated
-0.30%